(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Longeveron's earnings in 2025 is -$25,574,000.On average, 3 Wall Street analysts forecast LGVN's earnings for 2025 to be -$20,513,219, with the lowest LGVN earnings forecast at -$22,213,773, and the highest LGVN earnings forecast at -$18,011,167.
In 2026, LGVN is forecast to generate -$19,812,284 in earnings, with the lowest earnings forecast at -$21,763,494 and the highest earnings forecast at -$17,861,074.